Detailed Information
Cited 0 time in 
Cited 3 time in 
Cited 3 time in
Metadata Downloads
A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabineopen access
- Authors
- Yi, J.H.; Park, S.; Kim, J.H.; Won, Y.-W.; Lim, D.H.; Han, B.; Uhm, J.; Kim, H.S.; Jung, C.W.; Jang, J.H.
- Issue Date
- Jan-2018
- Publisher
- Impact Journals LLC
- Keywords
- Acute myeloid leukemia; Decitabine; Elderly patients
- Citation
- Oncotarget, v.9, no.5, pp 6607 - 6614
- Pages
- 8
- Journal Title
- Oncotarget
- Volume
- 9
- Number
- 5
- Start Page
- 6607
- End Page
- 6614
- ISSN
- 1949-2553
- Abstract
- Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients. © Yi et al.
- Files in This Item
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.